Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. - Wikidata - wikimedia - TriplyDB

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

http://www.wikidata.org/entity/Q35996636

about

Long-term drug treatment for obesity: a systematic and clinical review Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review Evaluation and Treatment of Severe Obesity in Childhood.Liraglutide and obesity: a review of the data so far.Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.The prevention and treatment of obesity.Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.Small lipidated anti-obesity compounds derived from neuromedin U.Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.Effects of glucagon-like peptide-1 receptor agonists on renal function Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity.Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.Liraglutide for weight management: a critical review of the evidence.Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.

P2860

Q22253010-01B6E75A-1FB1-4B14-8D0B-2EC2F87A952C Q27012801-7DC5B277-A649-4133-8EEB-7FF89C48324E Q28076726-0DFA751F-8510-46D1-A39E-FDEA1E18E6D2 Q30300992-D0B42DF9-EEF0-499B-86A7-FE5E7AF7C84F Q30924982-3E383BB0-5B6C-4BD4-86E1-7050B54923F2 Q31167862-88E4E818-D7D9-4B70-B92D-548424B4A2CB Q33607749-E59E702C-E0FD-4439-A15D-9FE6FA0FE231 Q34521259-E2253125-F57B-4457-A702-B0FC0DD73248 Q35209811-1A71BECC-5399-4B15-A432-80ADDF3B4907 Q35708420-D2925D77-028A-49AF-9848-DEC0F7E7F442 Q36284121-7B676E1F-99B0-4BEE-BBFD-71149EF5650F Q36709118-37922610-6E85-4F86-A94B-52E3067407F7 Q37232679-23841A32-6403-433E-9D8C-A66A9454B2D3 Q37402786-668C98DB-E63A-4E1D-8012-97207E10EBE8 Q37501257-424C1441-234E-40C1-80CF-248794654A4F Q37562586-ADAA0D70-9D87-48DF-990F-54330556FFF5 Q37581317-A569ADC7-D4C8-4A9B-87F2-0AE714C8821D Q37711170-B28044BB-F147-4DD7-912D-19FF7E099DE0 Q38243035-EBBEFCF9-D2B1-4DF1-A15F-8DCF6486EBBC Q43446368-9F309D4E-1B25-47CF-BF18-3E7720A4AFB0 Q46637270-021C02C8-1A10-434C-B202-32BDD832E064 Q47154668-72984D2D-DE31-40F9-9FC2-0306E2D18A90 Q48339050-9B6C282A-D6F6-49E3-A03E-6EBEA85114F7 Q51278208-90AAB04B-486D-4C75-B0AC-213CD1C8EA37

P2860

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

http://www.wikidata.org/entity/Q35996636

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

@ast

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

@en

type

label

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

@ast

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

@en

prefLabel

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

@ast

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

@en

P1433

Q35996636-C1FD6851-0456-44E5-992D-8CA14E206B86

P1476

Q35996636-6F08AC8E-C105-437D-8626-55033AABBBD2

P2093

Q35996636-7213D2B8-4D61-4BB3-BC53-D07EE854A812

Q35996636-8089C7EA-4704-4559-BC53-A4440215D124

Q35996636-F5842027-F876-4A88-A69B-4D3B641FD8C3

Q35996636-FB085ED6-B073-4616-B537-10B4E48318B7

P2860

Q35996636-002E757A-8B75-4B73-A09E-B15411D0C72E

Q35996636-1331A333-C148-449A-869B-AF6C0AC22027

Q35996636-23B355B6-E7D7-4DC7-8641-6EB33A4FD50C

Q35996636-253B3863-D0B8-40A7-AF64-C54865F2BE66

Q35996636-26208AF3-4389-4F9E-B28D-9A169878B8C9

Q35996636-26E7F44A-510F-4F5E-9B5F-16EAA34B2019

Q35996636-393811C1-E6F9-45DC-BD4E-11F07F1ABC84

Q35996636-4937BF27-81E0-454A-99EF-01649543E29D

Q35996636-4E648FB6-1B9D-4E92-8C6F-FA6C9814A2C2

Q35996636-573ED466-4550-4EDC-A1C7-B2D8212E41E6

P304

Q35996636-0933E4D1-1DCF-4821-9BD5-C57A3CB81BE9

P31

Q35996636-253b5b52-540c-4770-a70f-32e0ee221d8c

Q35996636-F262B957-8B52-494A-A0C8-A331AD699BE5

P356

Q35996636-6CEF87E2-7D13-434D-A3E5-AECE3F237FFC

P478

Q35996636-3DF58D92-994D-43C6-AB52-F67E73BD993D

P50

Q35996636-6BB72580-97BC-4851-A417-AFD01DE5E43F

P577

Q35996636-C29D6495-DEC1-47AC-A8A7-75E99019EC5F

P5875

Q35996636-384E74D1-32EE-46F3-B683-FCB67DC2E57C

P698

Q35996636-33537217-5518-4F30-BE04-853F106E2CA2

P932

Q35996636-0DDED0F2-8439-4BF9-9CD6-6DDA2B8C9FA7

P356

P1433

Experimental Diabetes Research

P1476

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

@en

P2093

Carlo M Rotella

http://www.w3.org/2001/XMLSchema#string

Edoardo Mannucci

http://www.w3.org/2001/XMLSchema#string

Matteo Monami

http://www.w3.org/2001/XMLSchema#string

Niccolò Marchionni

http://www.w3.org/2001/XMLSchema#string

P2860

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

Mechanisms of action of glucagon-like peptide 1 in the pancreas

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

GLP-1 for type 2 diabetes.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

P304

672658

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/672658

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P50

Ilaria Dicembrini

P577

2012-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225276472

http://www.w3.org/2001/XMLSchema#string

P698

22675341

http://www.w3.org/2001/XMLSchema#string

P932

3362858

http://www.w3.org/2001/XMLSchema#string